Kernicterus (muscle tone changes) - Causes, Treatment & When to See a Doctor

```html

What is Kernicterus (muscle tone changes)?

Kernicterus is a rare but serious form of brain injury that occurs when high levels of unconjugated bilirubin (a yellow pigment produced from the normal breakdown of red blood cells) cross the blood‑brain barrier and deposit in the basal ganglia and brainstem. The basal ganglia are critical for controlling movement, muscle tone and coordination; therefore, when bilirubin damages these structures the child may develop abnormal muscle tone – either floppiness (hypotonia) or increased stiffness (hypertonia/spasticity).

Although the term “kernicterus” historically referred to the permanent neurologic sequelae of severe jaundice, contemporary clinicians use it to describe the acute neurotoxic phase (sometimes called “acute bilirubin encephalopathy”) and the chronic phase (the permanent kernicterus syndrome). Prompt recognition of muscle‑tone changes can be lifesaving and may prevent irreversible damage.

Common Causes

Most cases of kernicterus are precipitated by unchecked neonatal hyperbilirubinemia. Below are the most frequent pre‑disposing conditions (both inherited and acquired) that raise bilirubin to neurotoxic levels.

• Hemolytic disease of the newborn (HDN) – ABO or Rh incompatibility: Maternal antibodies destroy fetal red cells, producing a rapid rise in bilirubin.
• Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency: Oxidative stress (e.g., infection, certain foods, drugs) triggers hemolysis.
• Hereditary spherocytosis or other red‑cell membrane disorders: Shortened red‑cell lifespan leads to chronic bilirubin production.
• Crigler‑Najjar syndrome type I: A genetic absence of the enzyme UDP‑glucuronosyltransferase results in severe unconjugated hyperbilirubinemia.
• Breast‑feeding jaundice & breast‑milk jaundice: Inadequate intake or substances in breast milk can impair bilirubin clearance.
• Prematurity (especially < 35 weeks gestation): Immature liver conjugation capacity and a higher proportion of fetal hemoglobin increase bilirubin load.
• Sepsis or severe infection: Inflammation reduces bilirubin uptake by the liver and may cause hemolysis.
• Perinatal asphyxia: Hypoxia compromises liver perfusion, limiting bilirubin conjugation.
• Medications that displace bilirubin from albumin (e.g., sulfonamides, certain antibiotics): Increase the free, neurotoxic fraction.
• Genetic polymorphisms in the UGT1A1 gene (Gilbert’s syndrome) combined with other risk factors: Mildly reduced conjugation can become clinically important when other stresses are present.

Associated Symptoms

Muscle‑tone abnormalities rarely appear in isolation. They are usually accompanied by other neurologic and systemic signs of acute bilirubin encephalopathy:

• Jaundice that extends beyond the first week of life or progresses despite phototherapy.
• Persistent lethargy or poor feeding.
• High‑pitched cry or, conversely, a weak, absent cry.
• Arching of the back (opisthotonus) – a classic sign of increased tone.
• Hypotonia – “floppy” limbs, especially noticeable when the infant is lifted.
• Seizures (often focal, but can become generalized).
• Auditory dysfunction (e.g., absent startle reflex) because the brainstem is involved.
• Ataxia or poor motor coordination emerging weeks to months later.
• Developmental delays, especially in speech and fine motor skills, as the child ages.

When to See a Doctor

Newborns and infants with any of the following warrant urgent medical evaluation:

• Visible yellowing of the skin or sclera that reaches the abdomen or legs.
• Muscle tone that is unusually stiff (arms/legs “cannonball” posture) **or** unusually floppy (limbs feel limp when moved).
• Difficulty waking the baby for feeds, or a marked decrease in feeding.
• Persistent high‑pitched cry or a sudden loss of cry.
• Seizure‑like activity (stiffening, rhythmic jerking, eye rolling).
• Any newborn with known risk factors (e.g., prematurity, HDN, G6PD deficiency) who develops jaundice after 24 hours of age.

If any of these signs are present, contact your pediatrician, neonatology service, or go to an emergency department **immediately**.

Diagnosis

Diagnosing kernicterus involves confirming dangerously high unconjugated bilirubin and assessing neurologic involvement.

Laboratory Evaluation

• Total serum bilirubin (TSB) and direct vs. indirect fractions: Levels >20 mg/dL (340 µmol/L) in term infants, or lower thresholds in pre‑terms, signal high risk.
• Serum albumin: Low albumin reduces bilirubin‑binding capacity, increasing free bilirubin.
• Blood type & Coombs test: Detects maternal‑fetal blood group incompatibility.
• G6PD screening: Especially in populations where deficiency is common.
• Genetic testing (if indicated): For Crigler‑Najjar, Gilbert or other UGT1A1 mutations.

Neurologic Assessment

• Detailed physical exam focusing on tone, reflexes, eye movements, and auditory startle.
• Scoring systems such as the BIND (Bilirubin‑Induced Neurologic Dysfunction) score help gauge severity.

Imaging & Ancillary Tests

• Transcranial ultrasound or MRI: May show hyperintensity in the basal ganglia in chronic kernicterus.
• Audiology testing: Early brainstem auditory evoked response (BAER) to detect hearing loss.
• EEG: Useful if seizures are suspected.

Treatment Options

Treatment aims to (1) rapidly lower the serum bilirubin, (2) prevent bilirubin from re‑entering the brain, and (3) support the infant’s overall health.

Medical Interventions

• Phototherapy (blue‑light therapy): The first‑line treatment; converts bilirubin into water‑soluble isomers that can be excreted without conjugation. Intensive (double‑surface) phototherapy is used for bilirubin ≥20 mg/dL in term infants.
• Exchange transfusion: Indicated when bilirubin exceeds the exchange‑transfusion threshold (≈25 mg/dL in term infants) or when neurologic signs appear despite phototherapy. This removes bilirubin‑laden red cells and replaces them with donor blood.
• Intravenous immunoglobulin (IVIG): May be used in hemolytic disease of the newborn to reduce antibody‑mediated hemolysis.
• Pharmacologic agents (e.g., metalloporphyrins): Still investigational but aim to block bilirubin production.

Supportive & Home Care

• Ensure adequate feeding (breast‑ or formula‑feeding) to promote stool passage of bilirubin.
• Monitor weight gain daily; poor weight gain can exacerbate hyperbilirubinemia.
• Maintain a warm, well‑ventilated environment around the infant during phototherapy (avoid overheating).
• Follow‑up appointments within 24‑48 hours after discharge to re‑check bilirubin levels.

Long‑Term Management

• Early intervention services (physical, occupational, speech therapy) for children with persistent tone abnormalities.
• Hearing aids or cochlear implants if audiology shows permanent loss.
• Regular neurodevelopmental assessments through childhood.

Prevention Tips

Most cases of kernicterus are preventable with early detection and treatment of jaundice.

• Screen newborns for risk factors: Blood type, Coombs test, G6PD status, and gestational age.
• Measure bilirubin levels before discharge: Use transcutaneous bilirubinometry or serum testing, especially in the first 48 hours for high‑risk babies.
• Encourage early and frequent feeding: Breastfeeding at least 8‑12 times per day helps eliminate bilirubin via stool.
• Educate parents on “yellow warning signs”: Show pictures of the progression of jaundice (head → chest → abdomen → legs).
• Avoid medications that displace bilirubin from albumin: Discuss any prescribed antibiotics or sulfonamides with a pediatrician.
• Promptly treat underlying hemolysis: For HDN, give Rh immunoglobulin (Rho(D) immune globulin) to Rh‑negative mothers.
• Use home phototherapy units only under medical supervision: Improper intensity can be ineffective.
• Schedule follow‑up bilirubin checks for premature infants: Their risk persists for several weeks.

Emergency Warning Signs

References

1. Mayo Clinic. “Kernicterus.” https://www.mayoclinic.org. Accessed May 2026.
2. American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” Pediatrics, 2022.
3. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Neonatal Jaundice.” https://www.niddk.nih.gov. Accessed May 2026.
4. World Health Organization. “Guidelines for the Management of Neonatal Jaundice.” WHO, 2021.
5. Cleveland Clinic. “Bilirubin Encephalopathy (Kernicterus).” https://my.clevelandclinic.org. Accessed May 2026.
6. Bhutani, V. K., et al. “Predictive Model for Significant Hyperbilirubinemia in Near‑Term and Term Newborns.” Pediatrics, 2020.

```